Surfing MASH

S5-E23 - 𝗟𝗲𝘀𝘀𝗼𝗻𝘀 𝗳𝗿𝗼𝗺 𝗘𝗔𝗦𝗟 𝗖𝗼𝗻𝗴𝗿𝗲𝘀𝘀: Challenges in Provider-Patient Communication Louise Campbell leads a discussion about challenges in provider-patient communication with Shira Zelber-Sagi and Mike Betel, who chaired a session on this topic at the EASL Congress 2024, and Tom Marjot and Jose Willemse, who were panelists for the discussion. https://hubs.la/Q02GpxJL0 #Provider-patientCommunication #EASLCongress #MotivationalInterviewing #NASHpodcast #SurfingNASH #FattyLiver

𝗕𝗮𝗿𝗶𝗮𝘁𝗿𝗶𝗰 𝘀𝘂𝗿𝗴𝗲𝗿𝘆 𝗶𝗻 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝘄𝗶𝘁𝗵 𝗰𝗶𝗿𝗿𝗵𝗼𝘀𝗶𝘀 𝗿𝗲𝗱𝘂𝗰𝗲𝗱 𝟭𝟱-𝘆𝗲𝗮𝗿 𝗠𝗔𝗟𝗢 𝗿𝗶𝘀𝗸 𝗯𝘆 𝟳𝟮% 𝗮𝗻𝗱 𝗳𝗶𝗿𝘀𝘁 𝗱𝗲𝗰𝗼𝗺𝗽𝗲𝗻𝘀𝗮𝘁𝗶𝗼𝗻 𝗯𝘆 𝟴𝟬%. In the SPECCIAL study from Cleveland Clinic, researchers analyzed 62 metabolic surgery patients and 106 nonsurgical control patients, all with compensated MASH-related cirrhosis. Follow-up was over a 25-year period with a mean follow-up of 10.0±4.5 years. The primary outcome, Major Adverse Liver Outcome (MALO), included first occurrence of ascites, variceal hemorrhage, hepatic encephalopathy, hepatocellular carcinoma, liver transplantation, or all-cause mortality. Secondary outcome, the progression to decompensation, included first occurrence of ascites, variceal hemorrhage, or hepatic encephalopathy. Read More: https://hubs.la/Q02FPLfH0 #MASHcirrhosis #bariatricsurgery Cleveland Clinic

𝗤𝘂𝗲𝘀𝘁𝗶𝗼𝗻 𝗼𝗳 𝗧𝗵𝗲 𝗪𝗲𝗲𝗸 “How can your organization support Healthy Livers, Healthy Lives in raising MASLD awareness among key stakeholders?” Comment your answer below, or to have your answer mentioned in the next episode recording: https://lnkd.in/eiq4AF4g #QuesitonOfTheWeek #FattyLiver #QoW #SurfingMASH

S5 - E22 - 𝗛𝗲𝗮𝗹𝘁𝗵𝘆 𝗟𝗶𝘃𝗲𝗿𝘀, 𝗛𝗲𝗮𝗹𝘁𝗵𝘆 𝗟𝗶𝘃𝗲𝘀: A Global SLD Public Health Coalition Jeffrey V. Lazarus, Chair of Healthy Livers, Healthy Lives, joins the Surfers to discuss this global SLD Public Health coalition. and the role of "top-down" solutions. https://hubs.la/Q02FmMbk0 #HealthyLiversHealthyLives #MASLD #SLDPublicHealth #NASHpodcast #SurfingNASH #FattyLiver

S5-21.6 - From the Vault: Comments on the 2023 AASLD Revised Practice Guidance Looking back 17 months to the publication of revised AASLD Practice Guidance. https://hubs.ly/Q02DWSRR0 #MASH #MASLD #AASLD #PracticeGuidance #NASHpodcast #SurfingNASH #FattyLiver

“How readily do you believe the CPG guidelines will be implemented, and which sections do you anticipate will be easiest and hardest to implement?” Comment Below or Answer Here: https://hubs.la/Q02DVtVv0 #QuesitonOfTheWeek #FattyLiver #Podcast

S5-E21 - 𝗥𝗲𝘃𝗶𝗲𝘄𝗶𝗻𝗴 𝘁𝗵𝗲 𝗨𝗽𝗱𝗮𝘁𝗲𝗱 𝗘𝗦𝗟-𝗘𝗔𝗦𝗗-𝗘𝗔𝗦𝗢 𝗠𝗔𝗦𝗟𝗗 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗣𝗿𝗮𝗰𝘁𝗶𝗰𝗲 𝗚𝘂𝗶𝗱𝗲𝗹𝗶𝗻𝗲𝘀 Co-authors Elisabetta Bugianesi and Frank Tacke join Louise Campbell and Roger Green to discuss the new MASLD Clinical Practice Guidelines from EASL, EASD and EASO. https://hubs.la/Q02DFbN00 #MASLD #CPG #EASL #EASD #EASO #NASHpodcast #SurfingNASH #FattyLiver Echosens @Madrigal Pharma, Novo Nordisk Eli Lilly and Company @easl news

Do you know the answer? 𝗤𝘂𝗲𝘀𝘁𝗶𝗼𝗻 𝗼𝗳 𝗧𝗵𝗲 𝗪𝗲𝗲𝗸: “What 3 drugs do you predict will be most commonly used to treat advanced fibrosis (F2-F3) in 3-5 years, and why these?” Comment below or answer here: https://hubs.la/Q02D0SXX0 #QuestionoftheWeek #weeklyquestion #fattyliver #fibrosis #advancedfibrosis

S5-E20 - Lessons from 𝗘𝗔𝗦𝗟 𝗖𝗼𝗻𝗴𝗿𝗲𝘀𝘀 𝟮𝟬𝟮𝟰: Exciting Advances in Drug Development Naim Alkhouri, MD, FAASLD and Mazen Noureddin, MD, MHSc join co-hosts Jörn M. Schattenberg and Roger Green to discuss the major drug development stories from the EASL Congress 2024. https://hubs.la/Q02CK93G0 #Tirzepatide #Survodutide #Efruxifermin #EASLDrugDevelopment #NASHpodcast #SurfingNASH #FattyLiver 89bio Akero Therapeutics Boehringer Ingelheim Inventiva Pharma Madrigal Pharmaceuticals Novo Nordisk Sagimet Biosciences Ionis Pharmaceuticals, Inc. TAKEDA PHARMACEUTICALS AMERICA, INC. Merck Altimmune, Inc. Eli Lilly & Company Boston Pharmaceuticals

“What kinds of support and education must we provide for primary care to become primary caregivers in MASLD, and how many years do you anticipate it will take for them to do so?” Answer in the comments below… or here: https://hubs.la/Q02CdjVy0 #SurfingMASH #QuestionOfTheWeek #FattyLiver